Cite
APA Citation
Wollin, L., Distler, J. H., Denton, C. P., & Gahlemann, M. (2019). rationale for the evaluation of nintedanib as a treatment for systemic sclerosis–associated interstitial lung disease. Journal of scleroderma and related disorders, 4(3), 212–218. http://access.bl.uk/ark:/81055/vdc_100088184938.0x000009